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ABSTRACT 
Title: Atrial fibrillation and its association to cardiac function and structure in cardiovascular 
disease 
Aim: To study associations between atrial fibrillation (AF) and echocardiographic measures 
of left atrial (LA) and left ventricular (LV) parameters in patients with underlying 
cardiovascular disease. 
Hypothesis: LA and LV dysfunction can predict AF in heart failure (HF) or ischemic stroke. 
Background: AF is a cardiac arrhythmia characterized by irregular ventricular rhythm 
caused by permanent or paroxysmal loss of normal sinus node function. AF is prevalent (3%) 
and rises sharply with age and with increasing severity of HF (40-60%). 
Methods: Study I: Elderly patients with chronic HF (n=67) were retrospectively analysed for 
LV systolic and diastolic function: Study II: Patients with an ischemic stroke/TIA (n=174) 
without known AF were prospectively analysed by echocardiography including Tissue 
Doppler Imaging (TDI) for LA and LV function. Electrocardiographic screening was used 
during follow up to detect AF. 
Results: Study I: AF was found in 41 patients (61%). Ejection fraction was higher (p<0.01), 
LV volume indices were smaller (p<0.001) and LV concentric hypertrophy was more 
common (p<0.05), transmitral early wave deceleration time was shorter (p<0.05) and 
pulmonary S/D ratio lower (p<0.001) in AF compared to SR patients. Study II: AF was 
found in 15 patients (8.6%) during 30 days follow up. The AF patients had higher LA volume 
index (LAVI, p<0.05), lower peak velocities during atrial contraction (A´, p<0.05), and 
higher ratio LAVI/A´ (p<0.01). LAVI and LAVI/A´ predicted AF by ROC analysis (AUC 
0.71-0.78). 
Conclusions: AF in chronic HF and ischemic stroke indicates a different patient population 
compared to normal rhythm with signs of diastolic dysfunction or abnormal LA function. 
Echocardiography using TDI can predict AF after ischemic stroke and gives an incremental 
value together with electrocardiographic methods to improve screening for AF. 
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY. 
 Atrial fibrillation, (AF) is the most common rhythm disorder in the population 
and the prevalence increases with age (1). The condition is sometimes easy to 
diagnose using a standard 12 lead electrocardiographic (ECG recording). 
However, there is a wide variation of symptoms, some of the patients are 
totally asymptomatic (silent AF) and are not aware about the presence of AF. 
Others have episodic AF (paroxysmal or persistent AF), with or without 
symptoms. 
In Swedish studies, the prevalence is recently approximated to 3 % of the 
population (2). Because of the lack of symptoms in some cases, the current 
prevalence of AF is probably underestimated. The detection rate has been 
improved by screening of the elderly population with known risk factors for 
AF (3). Local information activities in the primary care setting makes people 
more aware about the AF condition and its intertwined high risk of 5-7% 
yearly risk of thromboembolic complications. 
1.2 DEFINITION OF ATRIAL FIBRILLATION 
According to current guidelines (4, 5) AF is defined as: standard ECG shows 
irregular RR intervals, i.e RR intervals do not follow a repetitive pattern. 
There are no distinct P waves on the ECG. Some apparently regular atrial 
electrical activity may be seen in some ECG leads most often lead V1. The 
atrial cycle length (when visible), i.e. the interval between two atrial 
activations, is usually variable and >200 ms, corresponding to a heart rate of 
>300 atrial activations per minute. AF is considered to be  paroxysmal (PAF) 
if the attacks are recurrent but terminate spontaneously within seven days. AF 
which do not terminate in seven days or need prior DC-cardioversion/ 
pharmacological agents is defined to be persistent. When no attempt is made 
to restore sinus rhythm, AF is defined as permanent. 
 
1.3 COMORBIDITY AND ATRIAL FIBRILLATION 
 AF without structural changes in the heart is found predominantly in younger 
subjects and is termed lone AF, which is considered to be associated with a 
good prognosis (6). However, it is suggested that this entity is quite rare 
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because of the emerging modern diagnostic imaging techniques which can 
detect early and subtle signs of abnormal cardiac function (7). In elderly 
subjects, AF is often accompanied with other diseases, such as hypertension, 
diabetes, congestive heart failure (CHF) and coronary artery disease. CHF in 
combination with AF is very common. In the large Swedish national registry 
RiksSvikt, AF is present in approximately 40-50 percent of the study 
population (8). In patients with CHF and preserved ejection fraction (HFPEF), 
there are indications suggesting the proportion of AF increases to over 60% 
with the concomitant diagnosis of AF (9). Further, the proportion of AF 
increases with severity of CHF (10). 
It is important to identify and assess the risk profile including comorbidity for 
all individuals having AF. A substantial amount of data from the Framingham 
cohort study with a follow up time of more than 24 years have established a 
fivefold increase in risk for stroke for persons with chronic AF (11, 12) 
compared to no AF. In addition, more data are currently available describing 
the high risk for stroke with paroxysmal AF (PAF) which often is not fully 
treated with anticoagulants. This condition is often considered to be less 
harmful than chronic or permanent AF. A registry study from the largest 
hospitals of Scandinavia with a follow up time of six years confirms that the 
risk for stroke is twice in PAF compared to the general population and similar 
to the risk in permanent AF (13). It is thus very important to detect both 
symptomatic and silent AF because of the increased risk to develop 
thromboembolic complications, e.g. ischemic stroke. The prevalence of AF in 
patients with stroke is high, recent data says even higher than previously 
thought, 33% (14). Further, AF is shown to be an independent risk factor for 
myocardial infarction especially in women and in afroamerican cohorts (15). 
 
1.4 HISTORICAL ASPECTS 
In the ancient time in Greece, 2nd Century B.C., the Egyptian physicians were 
already aware about the heart and its function and structure. Symptoms and 
signs of illness were characterized and written down. In the early 19th Century 
the Egyptian papyrus was found by Egyptologists containing medical matters. 
Some of them were published by Georg Ebers in 1875 (the Ebers papyrus) 
Tachycardia and swelling of the limbs and dyspnoic symptoms were described 
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already in the 2nd century B.C. This could, with our knowledge today, clearly 
illustrate some of the clinical pictures of CHF with or without possible 
concomitant AF. 
The first ECG recordings were demonstrated in 1887 in London and later 
Willem Einthoven who was a professor of physiology from the Netherlands 
invented the string galvanometer and published his first article in 1903. In 1906 
the first clinical ECG was transmitted from the laboratory to a nearby 
Academic hospital via transtelephonic technique. 
The possibility to study the living and beating heart was an immediate 
diagnostic success when Inge Edler and Hellmuth Hertz in 1953 began to 
develop cardiac ultrasound and M-mode used to describe the mitral valve. 
Two-dimensional echocardiography was first demonstrated in the late 1950´s 
and with intracardiac probes in the 1960´s. Over time contrast 
echocardiography came in use in the 1960’s which increased the clinical 
applications and later two dimensional transesophageal methods emerged. 
Development of the pulsed Doppler method in the late 1960s opened up a new 
era for diagnostic opportunities to measure intracardiac blood flow and 
pressure gradients. The Doppler techniques continued to evolve, to study 
motion and deformation in tissues which opened up for more accurate 
evaluation of the cardiac physiology when combined with 2-dimensional 
recordings. Today echocardiography with Doppler is the most commonly used 
non invasive method and is now considered as a routine in clinical practice. 
 
1.5 SYMPTOMS AND DIAGNOSIS OF ATRIAL FIBRILLATION. 
The most common symptoms of AF are palpitations, fatigue and dyspnoea and 
patients are often admitted to hospital because of a rapid and irregular heart 
rhythm. The diagnosis is confirmed by an ECG . However, many patients are 
not aware of the rhythm disorder (16). Some patients develop stroke as the 
presenting and even first symptom of AF at admission to hospital when the 
diagnosis of AF is confirmed by ECG. In these cases stroke is a complication of 
AF when a thrombus formed in the left atrium embolizes to the brain. The 
challenge is to find asymptomatic subjects with an increased risk for 
complications (CHA2DS-Vasc-score), in particular stroke. If the diagnosis of 
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AF is confirmed, the involved physicians have a responsibility to minimize risk 
for tromboembolic complications, using anticoagulant therapy (4). 
The subjective symptoms might be difficult to interpret both for the patient and 
the physician. In the Classification list of symptoms adapted from the EHRA 
scoring system (European Heart Association), the severity of symptoms can be 
classified EHRA 1-5, and the higher score indicates more functional loss during 
everyday life (5). The Arrhythmia-Specific questionnaire in Tachycardia and 
Arrhythmia (ASTA HRQOL) is another method, trying to evaluate both 
physical and mental impairment of daily life activities in patients with 
arrhythmias in general. ASTA HRQOL has been found to be useful in the 
management and follow up of the medical or invasive treatment given to 
patients with AF (17). 
AF is often confirmed by an ordinary 12-lead ECG. But 12-lead ECG requires 
equipment and staff to be performed, and the arrhythmia must also be present at 
the same time. Patients very often present with a normal ECG on having 
reported discomfort from the chest and a sense of palpitations and irregularity 
of the pulse. In PAF, patients need repeated recordings of ECG or Holter 
monitoring to confirm the diagnosis. A thumb led ECG (ZENICOR Medical 
systems) is also in use, where patients can use this recorder in outdoor settings, 
and in a standardized manner to collect ECG data for a prolonged time over 
weeks (18). There are also implantable devices (REVEAL) from which data can 
be obtained for months or even years. Similarly the patients who carry a 
standard or other pacemaker (e.g. heart failure pacemaker [CRT]), the device 
can be interrogated on a regular basis to evaluate episodes of AF. 
 
1.6 ATRIAL FIBRILLATION AND EFFECTS ON CARDIAC FUNCTION 
 During normal sinus rhythm the cardiac cycle consists of a period of 
relaxation and filling of the ventricles, named diastole, followed by a period of 
contraction, named systole. Approximately 70 per cent of blood flows 
passively directly from the atria to the ventricles. Additionally 20-30 per cent is 
contributed when the atria contract. During diastole the ventricular volume 
increases. When AF occurs the atrial contribution to the ventricular filling is 
impaired leading to impaired cardiac output. Rapid tachycardia shortens the 
diastolic phase and the filling of the ventricle becomes inadequate. Rapid AF 
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can lower the systolic blood pressure due to reduced cardiac output. If the LV 
is already affected due to hypertrophy, dilation, valvular disease or chronic 
ischemic heart disease, the diastolic filling becomes complicated and the LV is 
more dependent on atrial contribution. An episode of rapid AF further impairs 
the hemodynamics leading to severe symptoms and acute decompensated heart 
failure (ADHF). The rate control is therefore one of the therapeutic options 
trying to stabilize the patient when restoration of sinus rhythm is not possible, 
especially in the elderly patients with CHF (19). 
 
1.7 THE LEFT ATRIUM 
During ventricular systole the atrium accumulates blood because of the 
closed atrioventricular valves. When pressure is falling in the ventricle the 
rapid filling phase occurs in early diastole when the atrioventricular valves 
open shortly after the phase of isovolumic relaxation. The atrium enhances 
ventricular filling by its contraction in sinus rhythm (SR) after a short period 
of almost no filling (diastasis). AF alters the intraatrial pressure and 
longstanding AF affects the volume of the left atrium which becomes 
enlarged. This is called structural remodeling and is a complex and not yet 
fully understood process. The enlargement and changes in the atrium are also 
followed by electrical remodeling which can further initiate and maintain AF 
(20). Also, there is some evidence that fibrosis of the left atrium is a promoting 
mechanism for development of AF in patients with CHF (21). The 
enlargement and increased volume of the left atrium is, however complex. 
Concomitant valve diseases , i.e. mitral regurgitation and stenosis, 
hypertension and diastolic LV dysfunction all contribute to volume changes of 
the atrium. The measurements of the left atrium are therefore important and 
the anatomic variations and the outlining of the atria must be considered. The 
appendage, the pulmonary veins and sometimes elongation of the atria could 
be troublesome when measuring the volume and atrial function. The most 
current and clinically available method for measuring of cardiac structure and 
function is 2-dimensional echocardiography (2DE) for calculation of left atrial 
volume (LAV) and this could be indexed to body surface area (LAVI) 
according to present guidelines (22). Other modalities like cardiac computed 
tomography (CCT) and cardiac magnetic resonance (CMR) are feasible if 
accessible in the clinic (23). 
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1.8.1    LEFT VENTRICULAR DIASTOLIC DYSFUNCTION 
The diastolic phase of ventricular filling in the cardiac cycle consists of four 
components: ventricular isovolumetric relaxation, rapid filling phase of the 
ventricle, diastasis, and filling during atrial systole. The LV function during 
diastole is dependent on relaxation and compliance (24). The left atrium 
contracts during the atrial systole (late filling) and when AF occurs this active 
phase disappears and the contribution to ventricular filling is impaired. An 
enlarged left atrium or LAVI is considered to be an indication of reduced 
ability to fill the LV and a strong indicator of LV diastolic dysfunction (25). 
The progression from normal diastolic function to impaired relaxation of the 
LV is an early sign of mild diastolic dysfunction. This is followed by moderate 
diastolic dysfunction, named pseudonormalization, with increased filling 
pressures and a subsequent decreased compliance. The restrictive filling stage 
or severe diastolic dysfunction is categorized with severely decreased 
compliance and increased filling pressure. This process leads to an enlargement 
of the left atrium, and molecular changes in the calcium and contractile 
elements and possible atrial remodeling (26, 27). Diastolic functional 
assessment is complicated, but can be measured by 2DE, pulse-wave Doppler, 
tissue Doppler imaging (TDI) and speckle tracking.  
There is no single measure to define diastolic function. An algorithm of several 
diastolic functional variables have to be used to categorize patients into one of 
the above categories of normal diastolic function, mild, moderate and severe 
diastolic dysfunction (24, 28, Figure below). Increase of end diastolic filling 
pressures is strongly associated with diastolic dysfunction and is also a 
hallmark of CHF. Filling pressure can be estimated noninvasively by Doppler 
echocardiography and TDI by using the E/E´ratio (29, 30). It is a particular 
challenge to measure diastolic function in patients with AF. However, LAVI, 
IVRT, DT, E/E´and pulmonary vein S/D ratio are possible to measure in AF. 
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Assessment of LV diastolic function using transmitral pulse-wave Doppler 
(e.g. E/A ratio, E-wave DT and A wave velocity) has been in use for a long 
time but these variables are dependent on age, LV loading conditions (filling 
pressures) and medication. TDI is presently used more mandatory and predicts 
changes in the regional left atrial systolic function and changes correlating to 
normal ageing (31, 32). The progress of diastolic dysfunction, the remodeling 
and enlargement of left atrium and risk for developing AF is complex and not 
fully understood. Hypertension and ischemic heart disease promote diastolic 
dysfunction (24). Longstanding AF usually causes enlargement and 
remodeling of the left atrium. However the largest study examining the 
relationship between AF and diastolic dysfunction with 4480 participants in the 
Cardiovascular Health Study with a follow up for 12 years, stated that LA 
dimension, transmitral E- and A-wave velocity were independent risk factors 
for AF (33). 
 
1.8.2   CARDIOPULMONARY EXERCISE TEST 
During exercise, muscle cells need carbohydrates and fat and together with 
oxygen uptake to produce energy, i.e aerobic metabolism. Level of consumed 
oxygen at rest and during exercise (VO2) is a measure of the amount of oxygen 
needed to produce the required energy during aerobic conditions. Carbon 
dioxide production (CO2) is the end product of oxidative metabolism such as 
the production of exhaled (VCO2) is measured to calculate energy use during 
aerobic and anaerobic conditions. The cardiopulmonary exercise test is used to 
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evaluate CHF patients. It is known that peak or maximal or peak ventilatory 
parameters e.g. VO2 and VCO2 and derived cardiopulmonary indices like the 
ratio between amount of ventilation (VE) and VCO2 (VE/VCO2) are strong 
prognostic markers for mortality in young and elderly patients with CHF (34). 
These parameters are commonly used to assess objective evidence of functional 
capacity and prognosis in CHF and in particular before heart transplant surgery. 
 Recently published data showed that AF patients with HFPEF had lower peak 
VO2 during exercise compared to patients in sinus rhythm (35). AF was a 
marker of severity of HF with larger LA volumes, impaired diastolic function 
but also worse systolic function (within the context of preserved EF) compared 
to the sinus rhythm group. This illustrates the possible impact that AF itself 
reduces the physical capacity even when LV function is preserved and rate 
control is adequate. Further, in AF there is an obvious impact of lower stroke 
volume and cardiac index by the loss of atrial filling of the ventricles. 
1.9 PROGNOSIS 
AF is a complex disease that can be associated with an increased risk for 
thromboembolic events. It coexists with several other chronic and progressive 
disorders which further promote the burden of AF. Repeated episodes of AF 
itself stimulate the remodeling process and enlargement of left atrium and a 
vicious circle appears where the arrhythmogenic substrate maintains itself in the 
end. The independent impact of AF on prognosis in cardiovascular disesase is 
difficult to establish because the high mortality can be associated to the 
treatment of AF or to the underlying cardiovascular disease. AF is not a strong 
independent predictor of mortality in CHF (36). Some antiarrhythmic agents 
have sideffects, and severe bleeding complications with warfarin and the novel 
anticoagulants can be seen. Catheter ablation is not a completely harmless 
treatment option and even after a routine cardioversion (DC shock) thrombus 
can be formed and embolized. 
The EURObservational Research programme- Atrial fibrillation General 
Registry Pilot phase collect data from 9 members of ESC countries and 3119 
subjects, and the follow up time was one year. Despite oral anticoagulation the 
mortality was high 5.7% and the cause of death was cardiovascular in 70% of 
cases (37). 
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2 AIMS 
1) To compare elderly hospitalized heart failure patients with or without AF 
with focus on echocardiographic and cardiopulmonary functional 
parameters. 
2) To investigate if echocardiography including TDI can detect unknown 
AF in patients with an ischemic stroke/TIA 
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3 MATERIAL AND METHODS 
3.1  SUBJECTS 
Study I 
The aim of this retrospective sub study was to compare elderly patients with 
CHF with or without AF regarding LV systolic and diastolic function. 
Patients were derived from The Optimizing Congestive Heart Failure 
Outpatient Clinic Project (OPTIMAL), which was a randomized prospective 
study in patients hospitalized with HF between January 1996 and December 
1999 at Danderyd University Hospital, a secondary referral center. 
Sixty-seven elderly patients (Table 1) (age 60 years or more, mean age 74 
years, female gender 34%) admitted to hospital due to CHF (NYHA class II-IV) 
and having an EF <45% or atrioventricular plane displacement (AVPD) less 
than 10 mm, were included. Subjects were divided into two subgroups, the 
sinus rhythm group (SR, n=26), and the atrial fibrillation group (AF, n=41). 
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Table 1 Demographic data at baseline 
n = 67 
 
Sinus rhythm 
n=26 
Atrial fibrillation 
n=41 
Age, mean (SD) 73 (7) 74 (6) 
Females/males, n/n 8/18 15/26 
Previous history n (%)   
Ischemic heart disease 21 (81) 23 (56) 
Hypertension 8 (31) 11 (27) 
Diabetes Mellitus 5 (19) 5 (12) 
Idiopathic cardiomyopathy 3 (12) 6 (15) 
Valvular disease 0 (0) 5 (12) 
Prior heart failure 13 (50) 18 (44) 
Medication n (%)   
Loop diuretics 24 (92) 39 (95) 
ACE-inhibitors 22 (85) 33 (81) 
Beta receptor blockade 12 (46) 28 (68) 
Digitalis glycoside 7 (27) 28 (68) 
n= number of patients. 
 
Study II  
The purpose of this sub study was to investigate if echocardiography including 
TDI at discharge, can predict unknown AF in patients after ischemic stroke. 
Study population was derived from the PROPP-STOPP study conducted at 
Danderyds University Hospital, Södersjukhuset Stockholm and Hallands 
Hospital between 2007 and 2010 with focus on prevalence and detection of 
unknown AF in stroke patients. 
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This prospective echocardiographic study included 174 consecutive patients 
(mean age 74 years, female gender 40%) admitted to hospital with an ischemic 
stroke/TIA and sinus rhythm at admission. Patients were included within two 
weeks after the event. History of prior AF was an exclusion criterion (Table 2). 
Table 2. Demographic data 
 All non AF AF P 
Number of patients 174 159 15  
Age years mean (range) 74 (48 - 91) 74 (48 - 91) 75 (65 - 84) 0.68 
Gender male 104 (60%) 98 (62%) 6 (40%) 0.10 
Smokers 19 (11%) 18 (11%) 1 (7%) 0.58 
Diabetes Mellitus 29 (17%) 28 (18%) 1 (7%) 0.28 
Congestive Heart Failure 7 (4%) 7 (4%) 0 (0%) 0.41 
Previous Stroke / TIA 39 (22%) 35 (22%) 4 (27%) 0.68 
Ischemic Heart Disease 41 (24%) 39 (25%) 2 (13%) 0.33 
Hypertension 112 (64%) 103 (65%) 9 (60%) 0.71 
Previous Palpitations 26 (15%) 22 (14%) 4 (27%) 0.18 
 
3.2 METHODS 
Study I 
All patients in this substudy were elderly patient with HF. After medical 
stabilization, echocardiography was performed and eligible patients with 
systolic dysfunction were enrolled. All echocardiographic measurements were 
calculated according to the American Society of Echocardiography using 
Acuson 128 XP/10 software. 
AF was detected in 41 subjects at ECG, Holter monitoring or during exercise 
test and was considered as AF group. The SR-group consisted of patients with 
no visible AF during hospital stay. A cardiopulmonary exercise test was 
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performed with sampling of peak VO2, peak respiratory equivalents for oxygen 
VE/VO2, carbon dioxide, VE/VCO2, VCO2/VO2) were calculated. Anaerobic 
threshold was estimated by the V-slope method. 
Blood sample for assessment of brain natriuretic peptide (BNP) was obtained 
after 30 min of supine rest. The blood sample was immediately centrifuged and 
the plasma was frozen until analysis. 
To asses the Quality of life in the HF patients, The Nottingham Health Profile 
(NHP) was used containing measurements of six different dimensions in this 
non disease specific questionnaire. 
The follow up data and outcomes of all cause mortality were determined from 
death certificates. Data regarding hospitalization rates were collected from the 
National board of Health and Welfare. 
 
Study II 
The second study is an echocardiograpic substudy including patients from the 
three participating centers in the PROPP-STOPP study. 
According to inclusion criteria all patients with prior known AF were excluded. 
2D echocardiography including TDI measurements was performed. Left atrial 
volume was indexed to body surface area (LAVI) and was measured according 
to the biplane Area-Length method. Atrial functional parameters, i.e. 
myocardial velocities during atrial contraction and during p-wave of the ECG 
(A´) in ventricular septum and atrial septum were recorded by colour coded 
TDI. The A´ in atrial septum was measured by placing the cursor on interatrial 
septum near the atrioventricular plane. The A´ at ventricular septum was 
recorded by placing the sample volume near the mitral annulus. Indices of 
LAVI divided by atrial and septal A´ (atrial and septal LAVI/A´) were 
calculated. Some other diastolic parameters were also measured, e.g. the ratio of 
early transmitral velocity to TDI mitral annular early diastolic velocity (E/E´) 
measured in basal septal and lateral walls and calculated as mean E/E´, 
transmitral E/A ratio, isovolumic relaxation time, and transmitral E-wave 
deceleration time (DT). In addition myocardial performance index (MPI), an 
expression of combined diastolic and systolic LV function was measured from 
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TDI based different time intervals of the cardiac cycle. LV mass and LV 
ejection fraction (LVEF) were also calculated. 
 
A compact disc with the full examination was sent from the centers to the core 
lab at Danderyd hospital. The echocardiographers were blinded for the ECG 
recordings until all data was collected and the study inclusion was stopped. A 
random control of 30 echocardiographic protocols were blindly reviewed to 
repeat echocardiographic accuracy of measurements. 
Finally echocardiographic data was evaluated to compare functional parameters 
in subjects who developed AF, during follow up participating the main study 
protocol, versus sinus rhythm. The primary hypothesis was that measures of 
diastolic function would be able to predict patients with later detected AF. 
 
Episodes of AF were detected with 24-hour -Holter monitoring and a previously 
validated  thumb held-ECG monitoring (Zenicor Medical Systems AB) in a 
standardized manner, twice daily and additional recordings if there were 
symptoms of palpitations. The observational time was 30 days after discharge. 
An episode of at least 10 seconds with irregular ventricular rhythm without p-
waves was defined as AF. 
3.3 STATISTICS 
Study I 
Data are presented as frequencies, median or mean values (SD), as appropriate. 
Pearson´s correlation coefficients were used when needed. Student´s t-test was 
used for comparison between two groups after checking for normally 
distributed data, if necessary log-transformation was performed before the test. 
The chi square two test with Yates correction was used for comparison of 
proportions. Mann-Whitney U-test was used to compare paired data if the 
material was not normally distributed. A power calculation showed that the 
present study sample size would be sufficient to detect a 20 % difference 
between the groups in peak VO2 and a 33% difference in EDVI with alpha 
=0.05 two-sided, and beta= 80%. A conservative approach with p-value < 0.001 
was considered statistically significant to correct for multiple testing and the 
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exploratory character of the study. The p-values shown in the tables are 
uncorrected. 
 
Study II 
The results for continuous data are presented as mean and one standard 
deviation or median and range as appropriate. Nominal data is presented as 
number and percentage of cases. For comparison between AF and non-AF 
groups, Students` t-test or Mann-Whitney U tests were used as appropriate. Chi 
square test was used to test differences in proportions. Receiver Operating 
Characteristics (ROC) analyses was performed for variables of interest to access 
the predictive ability to detect later occurrence of AF. All analyses were 
performed with Statistica (data analysis software system) version 10, StatSoft, 
Inc (2011), USA. No formal power calculation regarding echocardiographic 
measurements was performed in the original study protocol, the power analysis 
was performed for the primary endpoint detection of silent AF (14). 
 
3.4 ETHICS 
Both studies were performed in accordance with the Helsinki declaration and 
was approved by the regional ethical committee (95-207 and 2007/386-31/12;). 
Each patient gave written informed consent to participate in the studies. 
 
4 RESULTS 
4.1 STUDY I. DO ELDERLY HEART FAILURE PATIENTS WITH ATRIAL 
FIBRILLATION COMPARED TO SINUS RHYTHM HAVE SIGNS OF MORE OR 
LESS DETERIORATION IN CARDIAC FUNCTION AND CARDIOPULMONARY 
CAPACITY. 
Sixty-seven elderly patients with HF participated in this study. The 
demographic data at baseline showed no significant differences in previous 
history, medication or age. There were numerically more male participants in 
the AF group (63% vs 56%) and more patients with ischemic heart disease in 
the SR group (81% vs 56%). AF patients tended to have more treatment with 
digitalis (68% vs 27%). 
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Echocardiographic measurements (Table 3) showed generally higher EF in the 
AF group. Volumes indices of the LV were significantly smaller and the mitral 
E-Point septal separation (EPSS) was lower compared to the sinus group. Left 
atrial diameter and AVPD were similar in the two groups. LV mass index was 
high in both groups but diastolic parameters tended towards a shorter E-wave 
deceleration time and significantly lower ratio of pulmonary venous S-wave/D-
wave in the AF group. Further LV concentric remodeling was more frequent 
with AF. 
There were no differences in ventilatory parameters (Table 4) between the two 
groups. Peak oxygen consumption, ventilatory equivalents, anaerobic threshold 
and physical capacity were severely reduced in both groups. In the AF group 
resting and peak exercise heart rates were slightly higher. There were no 
differences in Quality of Life, NYHA functional class and BNP between the 
two groups. 
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Table 3 Echocardiographic variables 
 Units Sinus rhythm 
n=26 
Atrial fibrillation 
n=41 
p-values 
Left atrium  cm 4.7 (0.7) 4.6 (0.9) ns 
Septum  cm 1.1 (0.3) 1.3 (0.4) <0.05 
Posterior wall cm 1.0 (0.3) 1.1 (0.2) ns 
LVEDD cm 6.2 (1.1) 5.4 (0.9) <0.05 
LVESD cm 5.3 (1.3) 4.3 (1.2) <0.01 
EDVI ml/ m2 83 (29) 56 (24) <0.001 
ESVI ml/ m2 59 (25) 35 (19) <0.0001 
EPSS Cm 2.0 (0.9) 1.2 (0.6) <0.0001 
EF % 31 (10) 39 (10) <0.01 
AV-mean Cm 7.2 (2.0) 6.7 (2.0) ns 
AV-RV Mm 14.7 (4.9) 13.6 (4.7) ns 
LVMI g/m2 144 (39) 139 (36) ns 
LVH >125 g/m2  % 63% 59% ns 
RWT >0.45 % 21% 50% <0.05 
E deceleration 
time 
ms  207 (83) 170 (41) <0.05 
S/D ratio - 0.98 (0.48) 0.55 (0.44) <0.001 
Values are mean (SD), or proportions (%) as indicated. 
Abbreviations 
AV-mean  Atrioventricular displacement in mm  
AV-RV Atrioventricular displacement right ventricle in mm 
EDVI Enddiastolic volume index (ml/m2 BSA)  
ESVI Endsystolic volume (ml/m2 BSA) 
EPSS E-point septal separation 
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EF Ejection fraction 
FS Fractional shortening 
LVEDD Left ventricular enddiastolic diameter 
LVESD Left ventricular endsystolic diameter 
LVMI Left ventricular mass index 
LVH Left ventricular hypertrophy 
RWT Relative wall thickness 
S/D ratio Ratio pulmonary venous S-wave/D-wave 
 
Table 4 Cardiopulmonary exercise test parameters 
 Units Sinus rhythm 
n=26 
Atrial fibrillation 
n=41 
p-value 
VO2 AT ml/kg/min 8.4 (3.0) 7.2 (2.2) ns 
Peak VO2 ml/kg/min 12 (4.3) 11 (3.2) ns  
Peak VCO2/VO2 - 1.1 (0.1) 1.1 (0.1) ns 
Peak VE/VO2 - 44 (11) 47 (11) ns 
Peak VE/VCO2 - 42 (8.5) 44 (8.5) ns 
Exercise 
tolerance 
Watt 74 (29) 72 (29) ns  
Heart rate, rest 
Heart rate, peak 
Bpm 
Bpm 
70 (17) 
111 (18) 
83 (22) 
124 (30) 
<0.01 
ns 
Values are mean (SD). 
Abbreviations 
Bpm Beats per minute 
VO2 Oxygen consumption 
VCO2 Carbondioxide production 
VO2AT Oxygen consumption at anaerobic threshold 
VCO2/VO2 Respiratory quotient 
VE/VO2 Ventilatory equivalent for oxygen 
VE/VCO2  Ventilatory equivalent for carbondioxide 
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4.2 STUDY II. CAN ECHOCARDIOGRAPHY DETECT UNKNOWN ATRIAL 
FIBRILLATION IN PATIENTS WITH STROKE/TIA? 
From the Proppstopp study cohort, 174 consecutive enrolled patients underwent 
extensive echocardiographic evaluation with TDI measurements of atrial 
functional parameters. From the ECG recordings, 15 patients (8.6 %) were 
found to have AF during follow up. 
 Demographic data at baseline showed no significant differences between the 
AF and the SR group regarding previous history, age, or smoking habits. There 
was a weak trend for more women in the AF group (62% vs 40%, p=0.10). 
Echocardiography (Table 5) showed significantly larger LAVI, higher LAVI/A´ 
and lower A´ velocities in ventricular and atrial septum in the AF group. No 
significant differences were found between the groups regarding to LV, EF, 
LV-mass index, E/E´, other diastolic function variables and MPI. 
Receiver Operating Characteristics (ROC) for detection of paroxysmal AF 
(PAF) showed AUC for LAVI/A´ in atrial septum 0.78, 0.76 in ventricular 
septum and for LAVI 0.71. LAVI was possible to measure in 95% of the 
patients, LAVI/A´in ventricular septum in 93% and in atrial septum in 87% of 
the patients. 
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Table 5. Echocardiographic data 
 All non AF AF p 
LAVI, ml/m2 32.0 (8.6) 31.6 (8.6) 37.2 (6.7) 0.018 
A mitral inflow, cm/s 80.9 (26.2) 81.4 (25.3) 76.2 (35.3) 0.500 
A´ ventricular septum, cm/s 7.1 (1.7) 7.2 (1.6) 5.9 (2.2) 0.010 
A´atrial septum, cm/s 5.8 (1.4) 5.9 (1.4) 4.8 (1.4) 0.013 
LAVI/A´, ventricular septum 4.3 (3.2-5.8) 4.2 (3.2-5.5) 6.7 (5.0-8.7) 0.001 
LAVI/A´, atrial septum 5.3 (4.1-7.0) 5.1 (4.1-6.8) 8.5 (5.9-11.0) 0.003 
LV E/E´, mean 11.2 (3.8) 11.2 (3.9) 11.5 (2.9) 0.842 
E/A, ratio 0.85 (0.73-1.09) 0.84 (0.72-1.08) 0.92 (0.81-1.37) 0.054 
LV IVRT, ms 91 (25) 91 (25) 91 (25) 0.889 
LV DT, ms 247 (24) 247 (25) 252 (24) 0.435 
PVs/PVd 1.51 (0.41) 1.51 (0.42) 1.39 (0.35) 0.614 
PVa, cm/s 32.0 (28.0-38.0) 32.0 (28.0-39.0) 30.5 (29.0-33.0) 0.483 
LV mass index, g/m2 107 (22) 108 (23) 105 (22) 0.735 
LV EF, % 62.7 (8.9) 62.5 (9.1) 64.5 (6.8) 0.473 
LV MPI 0.51 (0.19) 0.51 (0.19) 0.54 (0.15) 0.553 
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5 GENERAL DISCUSSION 
 
For the individual patient AF is sometimes devastating due to the well known 
tromboembolic complications, i.e. stroke which can create a lifelong handicap 
and suffering for the patient and high rehabilitation costs for the society. The 
most important task today is to find patients with an increased risk for such an 
event. This would enable us to find and treat patients at risk for tromboembolic 
stroke because of silent or symptomatic AF. The risk factors are also well 
known from different studies (11, 13) and thus the CHA2DS2-VASC- score has 
been implemented for guidance in the every day clinical practice. The new era 
of novel oral anticoagulants as a complement to Warfarin should make it more 
convenient with medical treatments that suit more patients because of less need 
for therapy control. However, the challenge is to find all these patients who 
have silent or asymptomatic AF. Finding new tools and diagnostic procedures 
might help in decision making for individuals with severe risk for developing 
AF. 
 
5.1  ATRIAL FIBRILLATION, THE VICIOUS CIRCLE  
 
Left atrium is a very complex thin walled structure with contractile elements 
and excitable cells which initiate and conduct electrical impulses. It contributes 
to the cardiac output and can be an embolic source for formation of thrombus. 
Electrophysiologically the complexity about the triggers, the arrythmogenic 
substrate, the pulmonary veins and the electrical and structural remodeling is 
not fully understood. Today catheter ablation is used successfully in many 
patients to reduce AF burden and symptoms. However longterm results of 
efficacy are not available and information on outcome of ablation in CHF is 
lacking. 
However, from another point of view, one might consider the complex 
mechanism of structural remodeling and the comorbidities of AF to improve 
methods of screening and detection of AF. Hypertension and CHF enhances 
diastolic dysfunction (24, 25) and diastolic dysfunction is linked to increased 
LA size and volume (25, 28). AF is more than 10 times more frequent in CHF 
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compared to the population and it seems likely that the triggering mechanism 
for AF could be influenced by alterations in LV function and cardiac structure 
(33). As earlier stated the risk for developing AF is associated to both structural 
and electrical remodeling. In study I we compared elderly patients hospitalized 
with CHF. Heart failure patients with AF had a better EF, and smaller LV 
volumes indicating less deterioration of systolic function. Better EF by 6% was 
found with AF in a large registry study with unselected CHF patients to support 
our findings (38). In our study, peak VO2 was severely reduced in both SR and 
AF groups implying that AF is not only a finding of end stage CHF disease and 
AF itself may have an impact on cardiac function and functional capacity. The 
left atrial diameter was in our limited study not significantly larger with AF but 
the diastolic parameters such as shorter E-wave DT and lower pulmonary S/D- 
ratio support possible connections between AF and diastolic dysfunction as an 
important mechanism for evolution of AF (24, 33). Low S/D ratio has been 
found to predict elevated filling pressures in AF (39). These findings are further 
supported by the high proportion of AF found in HFpEF (9). In patients with 
HFpEF there is also a link between AF and increased risk of stroke (40). 
HFpEF is broadly defined as a preclinical state of diastolic dysfunction and 
remodeling of left atrium plays an important role in the pathophysiology and is 
associated with risk factors as diabetes, hyperlipidemia and peripheral vascular 
disease (41). Treatment of those risk factors is considered to stop the 
progression to diastolic dysfunction and CHF, AF and stroke. A single episode 
of AF should be treated according to the guidelines. Question might arise 
whether early treatment of AF can stop the remodeling process of the atrium 
and reduce AF burden. Secondly, whether catheter ablation should be combined 
with medical treatment. These considerations warrant further studies on this 
topic. 
 
5.2  IS ECHOCARDIOGRAPHY IMPORTANT FOR DECISION MAKING IN 
PATIENTS WITH STROKE?   
 
In study II we used standard echocardiography and TDI for prospectively 
measuring left atrial functional parameters and volume in patients admitted to 
hospital with stroke or TIA. We found larger LA volumes and lower intrinsic 
velocities in subjects developing AF under the follow up period using Holter 
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monitoring and thumb held ECG-device. The combined indexed volume/ 
velocities LAVI/A´ for both ventricular and atrial septum were also 
significantly higher. Our results are strongly supported by similar recent results 
from two other investigators (42, 43). Echocardiographic evaluation in our 
study was performed prior to discharge and it is unlikely that an episode of PAF 
with atrial stunning prior to echocardiographic examination could explain any 
change in velocities in the atrial wall. In patients with a high CHA2DS-VASc-
score and subjective episodes of palpitations or possible undiagnosed 
asymptomatic AF, this method could be of additional value for ruling out 
patients with low risk for tromboembolic complications, in accordance with 
ESC guidelines (4). This could facilitate the further evaluation of patients in the 
high risk group with abnormal LAVI or LAVI/A´indices to perform long term 
monitoring of ECG by available methods like Holter monitoring, telemetry at 
hospital or methods like thumb-ECG. 
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6 CONCLUSIONS 
Elderly hospitalized patients with CHF and AF, had more preserved systolic 
function and less dilated LV volumes but signs of more diastolic dysfunction 
compared to patients with CHF without AF. Exercise capacity is however 
reduced equally in both groups. Our results support the theory that AF is more a 
contributing factor to CHF than the mere consequence of end stage CHF 
disease. Secondly, we suggest that diastolic dysfunction or concentric 
remodeling may serve as important factors for the development of AF and 
further remodeling in patients with CHF. 
Standard echocardiography and TDI at discharge can be useful in decision 
making to follow up patients with high risk for tromboembolic events. LA 
volume and functional diastolic parameters LAVI/A´ in septal walls of LV and 
atrium may be used to rule out patients who need prolonged screening for AF.  
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7 FUTURE PERSPECTIVES 
 
AF is a complex disease with not yet fully understood links to electrical and 
structural changes of the heart and the left atrium. The connection between 
diastolic dysfunction and progression of heart failure and onset of AF is still 
unclear. The medical treatment of the arrhythmia itself and intensive treatment 
of other risk factors should be beneficial to improve prognosis. The screening of 
AF in the elderly population with increased risk is important and after a stroke 
or tromboembolic event, efforts must be made to rule out AF. 
Echocardiography with TDI can have an incremental value together with 
electrocardiographic methods to detect AF. More patients may be treated with 
the newer oral anticoagulants and the incidence of stroke may be decreased. 
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9 SVENSK SAMMANFATTNING 
Förmaksflimmer (FF) är en vanlig sjukdom i befolkningen som 
uppskattningsvis drabbar cirka 3%. Sjukdomen har ett brett panorama av 
symtom från ett helt asymptomatiskt stadium till svåra besvär med attacker med 
hjärtklappning, andfåddhet och nedsatt ork. I de högre åldersgrupperna ses 
förmaksflimmer vanligen tillsammans med andra sjukdomar som t ex. högt 
blodtryck, diabetes och hjärtsvikt. Med ökande ålder och andra samtidigt 
existerande sjukdomar ökar också  risken för komplikationer där den vanligast 
kända är stroke. Detta innebär en cirkulationsrubbning i hjärnan som ofta 
orsakas av att det bildas proppar i hjärtats vänstra förmak som tranporteras till 
hjärnan via blodströmmen. Förmaksflimmer diagnostiseras vanligen genom att 
registera hjärtrytmen via vanligt vilo-EKG eller med olika typer av bandspelar 
EKG där hjärtrytmen registeras under en längre tid.  
Syftet med den första studien har varit att jämföra äldre patienter med hjärtsvikt 
som lagts in på sjukhus. Patienter med eller utan FF har jämförts med avseende 
på hjärtfunktion, strukturella skillnader i hjärtats förmak och kammare samt 
förmågan till fysisk ansträngning kan påverkas vid flimmersjukdom. 
Den andra studien utfördes på patienter som insjuknat med stroke eller 
cirkulationstörning i hjärnan utan någon känd flimmersjukdom. Patienterna har 
följts upp med omfattande ekg registeringar under 24 timmar samt en 
långtidsregistering under 30 dagar för att påvisa flimmersjukdom. En 
omfattande ultraljudsundersökning av hjärtat med sk vävnadsdoppler (TDI) 
utfördes vid utskrivning för att kunna påvisa strukturella skillnader och 
hahstigheter i hjärtats förmak och kammare. 
Sammanfattningvis kan man säga att metoderna har påvisat skillnader i hjärtats 
struktur och funktion hos äldre patienter med hjärtsvikt och förmaksflimmer. 
Ultraljudsundersökning av hjärtat hos patienter med stroke kan komma att 
användas för att användas i screeningen av patienter där man ännu inte kunnat 
hitta förmaksflimmersjukdomen. 
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